{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:36Z","timestamp":1792815396329,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmoop.2025.105290","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:50:47Z","timestamp":1749822647000},"page":"105290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"K.","family":"Yonemori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105290_bib2","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/cancers15194689","article-title":"Estrogen receptor signaling in breast cancer","volume":"15","author":"Miziak","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105290_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/OP-24-00547","article-title":"Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO guideline clinical insights","volume":"21","author":"Makhlin","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2025.105290_bib4","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.3390\/curroncol30060411","article-title":"HR+\/HER2- advanced breast cancer treatment in the first-line setting: expert review","volume":"30","author":"Jerzak","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2025.105290_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.esmoop.2025.105290_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105290_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105290_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-21-0378","article-title":"Covalent ER\u03b1 antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer","volume":"21","author":"Furman","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2025.105290_bib10","series-title":"H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor-2 negative (HER2\u2212) advanced breast cancer\u2014a phase 2 study","author":"Hamilton","year":"2021"},{"key":"10.1016\/j.esmoop.2025.105290_bib11","series-title":"H3B-6545 in women with locally advanced\/metastatic estrogen receptor-positive, HER2-negative breast cancer","author":"Hamilton","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105290_bib12","series-title":"Phase 1 dose escalation of H3B-6545, a first-in-class highly selective ER\u03b1 covalent antagonist (SERCA), in women with ER-positive","author":"Hamilton","year":"2019"},{"key":"10.1016\/j.esmoop.2025.105290_bib13","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105290_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-023-00544-z","article-title":"Phase II trial of fulvestrant plus enzalutamide in ER+\/HER2- advanced breast cancer","volume":"9","author":"Elias","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105290_bib15","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105290_bib17","article-title":"H3B-6545 + palbociclib in patients (pts) with locally advanced\/metastatic estrogen receptor-positive (ER+), HER2 negative (\u2212) breast cancer (BC) (abstract)","volume":"42","author":"Johnston","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105290_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2025.105290_bib19","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105290_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","article-title":"The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition","volume":"30","author":"Terada","year":"2023","journal-title":"Breast Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925011597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:45:07Z","timestamp":1762598707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925011597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2059702925011597"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105290","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105291","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Eisai Inc. and The Author(s).  Published by Elsevier Ltd. On behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105290"}}